• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

VBI Vaccines

edit

VBI is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine development and growing pipeline of vaccine programs address significant market opportunities and are designed to answer critical unmet medical needs.

Founded in 2001, VBI is a privately held company headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. The company’s investors include Clarus Ventures, ARCH Venture Partners and 5AM Ventures.

Recent Milestones

edit

• 
  VBI Vaccines received $1.2M in Debt funding. (7/2/12)
  Posted 7/2/12 at 7:36pm via masshightech.com
• 
  VBI Vaccines received $2.2M in Debt funding. (2/13/12)
  Posted 2/13/12 at 7:46pm via masshightech.com
• 
  VBI Vaccines acquired Epixis. (9/15/11)
  Posted 9/15/11 at 8:50pm via masshightech.com
• 
  VBI Vaccines added Jeff Baxter as President and CEO.
  Posted 9/15/11 at 8:40pm
• 
  VBI Vaccines added Egidio Nascimento as CFO.
  Posted 9/15/11 at 8:40pm

Videos

Screenshots

edit

Above: Home page
Uploaded: 2/14/12

Sources

1. VBI acquires French vaccine developer Epixis (masshightech.com) [edit]
2. VBI Vaccines pulls in $2.2M debt round (masshightech.com) [edit]
3. VBI Vaccines raises $1.2M in debt financing (masshightech.com) [edit]